The transition to oral GLP-1 therapies is a significant market expander, not just a convenience upgrade. Nearly 80% of patients starting oral medications are new to the drug category, indicating a substantial increase in the addressable patient pool rather than simple conversion of existing users.
Despite intense media hype and rapid initial sales, GLP-1 therapies have only reached a fraction of their potential market. With just 6% of eligible obesity patients in the U.S. and 2% internationally currently on treatment, the runway for future growth remains immense.
The widespread adoption of GLP-1 therapies is projected to decrease total U.S. calorie consumption by 1.6% by 2035. This second-order effect will create significant disruption and headwinds for industries reliant on consumer food purchasing, including the CPG, retail, and restaurant sectors.